For a patient with atrial fibrillation and several risk factors for stroke, what is the most appropriate stroke prevention strategy?

Study for the Board Certified Cardiology Pharmacist Exam. Utilize flashcards and answer multiple-choice questions with detailed explanations. Prepare efficiently for your certification!

For a patient with atrial fibrillation and multiple risk factors for stroke, an ideal stroke prevention strategy would focus on anticoagulation to significantly reduce the risk of thromboembolic events. In this context, the use of direct oral anticoagulants (DOACs) such as rivaroxaban is strongly supported by clinical evidence.

Rivaroxaban, specifically at a dosage of 20 mg once daily, is indicated for stroke prevention in patients with non-valvular atrial fibrillation. This medication has been shown to be effective in reducing the risk of stroke and systemic embolism in this patient population. Its once-daily dosing is also convenient for patients, potentially enhancing adherence to the treatment regimen.

Moreover, rivaroxaban has a rapid onset of action, no requirement for regular monitoring of coagulation parameters, and reversibility with specific reversal agents, making it a preferred choice for anticoagulation in atrial fibrillation, particularly for patients with several risk factors for stroke, as indicated by scoring systems such as CHA2DS2-VASc.

In contrast, although the other options listed may offer benefits, they do not align as closely with the typical guidelines for stroke prevention in the context provided. Aspirin, while historically used

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy